Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
As per available reports about 3 Open Access articles, 26 Scientific conference Proceedings , 5 national symposiums and 16 speakers, 3 Editors on Key word the influenza vaccine in Global Events page. Global Events of Conference series are presently dedicated exclusively to influenza vaccine and about 2,070 articles are being published on Journal of Stem Cell Research & Therapy.
The influenza vaccine, also known as flu shot, is an annual vaccination using a vaccine that is specific for a given year to protect against the highly variable influenza virus. Each seasonal influenza vaccine contains antigens representing three (trivalent vaccine) or four (quadrivalent vaccine) influenza virus strains: one influenza type A subtype H1N1 virus strain, one influenza type A subtype H3N2 virus strain, and either one or two influenza type B virus strains. Influenza vaccines may be administered as an injection or as a nasal spray.The U.S. Centers for Disease Control and Prevention recommend that everyone over the ages of 6 months should receive the seasonal influenza vaccine. Vaccination campaigns usually focus on people who are at high risk of serious complications if they catch the flu, such as the elderly and people living with chronic illness or those with weakened immune systems, as well as health care workers. Most flu vaccines provide modest protection against contracting influenza, with the effect seasonably variable depending on antigenic drift. Some studies have concluded that there is little evidence for efficacy among the elderly, while others concluded that efficacy ranges from "acceptable" to "high" depending on the specific vaccine formulation. The composition of trivalent virus vaccines for use in the 2015–2016 Northern Hemisphere influenza season recommended by the World Health Organization on February 26, 2015 was: an A/California/7/2009 (H1N1)pdm09-like virus† an A/Switzerland/9715293/2013 (H3N2)-like virus a B/Phuket/3073/2013-like virus. The WHO recommends that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virusInfluenza research includes molecular virology, molecular evolution, pathogenesis, host immune responses, genomics, and epidemiology. These help in developing influenza countermeasures such as vaccines, therapies and diagnostic tools. Improved influenza countermeasures require basic research on how viruses enter cells, replicate, mutate, evolve into new strains and induce an immune response. The Influenza Genome Sequencing Project is creating a library of influenza sequences that will help us understand what makes one strain more lethal than another, what genetic determinants most affect immunogenicity, and how the virus evolves over time. Solutions to limitations in current vaccine methods are being researched. The rapid development, production, and distribution of pandemic influenza vaccines could potentially save millions of lives during an influenza pandemic. Due to the short time frame between identification of a pandemic strain and need for vaccination, researchers are looking at novel technologies for vaccine production that could provide better "real-time" access and be produced more affordably, thereby increasing access for people living in low- and moderate-income countries, where an influenza pandemic may likely originate, such as live attenuated (egg-based or cell-based) technology and recombinant technologies (proteins and virus-like particles). As of July 2009, more than 70 known clinical trials have been completed or are ongoing for pandemic influenza vaccines. In September 2009, the US Food and Drug Administration approved four vaccines against the 2009 H1N1 influenza virus (the 2009 pandemic strain), and expected the initial vaccine lots to be available within the following month. A quadrivalent flu vaccine administered by nasal mist was approved by the U.S. Food and Drug Administration (FDA) in March 2012. Fluarix Quadrivalent was approved by the FDA in December 2012
OMICS International Organizes 1000+ Global Events. Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Accesswhich contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The Conference serieswebsite will provide you list and details about the conference organize worldwide.
Scope & Importance Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies. Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017. Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines. A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers. Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.
: Conferences on Influenza vaccine: :
Protein Engineering Conference
October 26-28, 2015 Chicago, USA
Vaccines Middle East Conference
September 28-30, 2015 Dubai, UAE
Vaccines Asia Pacific Conference
November 10-12, 2016 Melbourne, Australia
Vaccines 2015
November 30-December 02, 2015 San Francisco, USA
Euro Vaccines Conference
June 16-18, 2016 Rome, Italy
Hepatities Vaccines Conference
June 16-18, 2016 Rome, Italy
Hiv Vaccines Conference
Oct 3-5, 2016 Miami, USA
Vaccines USA Conference
November 30-December 02, 2015 San Francisco, USA
Proteomics Conference
September 01-03, 2015 Valencia, Spain
World Proteomics Conference
March 29-30, 2016 Atlanta, USA
2015 IMMUNIZATION SUMMIT! NAMPA, IDAHO
MONDAY, SEPTEMBER 21, 2015
14th Annual Measles and Rubella Initiative Meeting: Focusing on the Human and Financial Costs of Measles Washington, USA
September 15-16, 2015
19th Annual Conference on Vaccine Research
April 18-20, 2016 Baltimore, MD
Clinical Vaccinology Course Bethesda, MD
November 13, 2015
9th Vaccine & ISV Congress
18-20 October 2015 | Lotte Hotel, Seoul, South Korea
2016 North Dakota State Immunization Conference
August 3-4, 2016, Bismarck, ND
Relevant societies and associations:
Immunization Action Coalition
The International Society for Vaccines
Center for Knowledge Societies
Applied Research on Cancer (ARC-NET)
The network of National Cancer Institutions of Latin America (RINC)
American Cancer Society
African Organization for Research & Training in Cancer (AORTIC)
GAVI, THE VACCINE ALLIANCE
Centre of Genomics and Policy (CGP)
Companies:
Vaccine Delivery Innovation Initiative
Four Seasons Pharmacy
Dubai Health authority
pfizer
Sanofi
GlaxoSmithKline
Novartis
MSD
Antivenom & vaccine Production centre
The centre for food security &public Health
National Institute of Agrobiological SciencesGenebank
merck
This page will be updated regularly.
This page was last updated on November 5, 2024
